KR20220010552A - 항-abeta 백신 요법 - Google Patents

항-abeta 백신 요법 Download PDF

Info

Publication number
KR20220010552A
KR20220010552A KR1020217041697A KR20217041697A KR20220010552A KR 20220010552 A KR20220010552 A KR 20220010552A KR 1020217041697 A KR1020217041697 A KR 1020217041697A KR 20217041697 A KR20217041697 A KR 20217041697A KR 20220010552 A KR20220010552 A KR 20220010552A
Authority
KR
South Korea
Prior art keywords
vaccine composition
liposomal vaccine
disease
administered
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217041697A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 파이퍼
안드레아스 무스
Original Assignee
에이씨 이뮨 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이씨 이뮨 에스.에이. filed Critical 에이씨 이뮨 에스.에이.
Publication of KR20220010552A publication Critical patent/KR20220010552A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217041697A 2019-05-21 2020-05-20 항-abeta 백신 요법 Pending KR20220010552A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP19175810.1 2019-05-21
EP19175810 2019-05-21
EP19185593.1 2019-07-10
EP19185593 2019-07-10
EP20171549 2020-04-27
EP20171549.7 2020-04-27
EP20172205 2020-04-29
EP20172205.5 2020-04-29
PCT/EP2020/064172 WO2020234405A1 (en) 2019-05-21 2020-05-20 Anti-abeta vaccine therapy

Publications (1)

Publication Number Publication Date
KR20220010552A true KR20220010552A (ko) 2022-01-25

Family

ID=70740677

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217041697A Pending KR20220010552A (ko) 2019-05-21 2020-05-20 항-abeta 백신 요법

Country Status (15)

Country Link
US (1) US20220226447A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972633A1 (cg-RX-API-DMAC7.html)
JP (1) JP7701734B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220010552A (cg-RX-API-DMAC7.html)
CN (1) CN113853214A (cg-RX-API-DMAC7.html)
AU (1) AU2020277682A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023209A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138145A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003051A1 (cg-RX-API-DMAC7.html)
IL (1) IL288252B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014102A (cg-RX-API-DMAC7.html)
MY (1) MY210394A (cg-RX-API-DMAC7.html)
SG (1) SG11202112329RA (cg-RX-API-DMAC7.html)
TW (1) TW202110425A (cg-RX-API-DMAC7.html)
WO (1) WO2020234405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI916375B (zh) * 2020-06-25 2026-03-01 英商梅迪繆思有限公司 軸突損傷之預防
WO2024156912A1 (en) * 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy
WO2025109524A1 (en) * 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta

Also Published As

Publication number Publication date
IL288252A (en) 2022-01-01
JP2022533422A (ja) 2022-07-22
MY210394A (en) 2025-09-18
CN113853214A (zh) 2021-12-28
CA3138145A1 (en) 2020-11-26
SG11202112329RA (en) 2021-12-30
JP7701734B2 (ja) 2025-07-02
IL288252B1 (en) 2026-06-01
TW202110425A (zh) 2021-03-16
US20220226447A1 (en) 2022-07-21
WO2020234405A1 (en) 2020-11-26
BR112021023209A2 (pt) 2022-01-18
MX2021014102A (es) 2022-02-11
EP3972633A1 (en) 2022-03-30
CL2021003051A1 (es) 2022-07-22
AU2020277682A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
KR100996936B1 (ko) 베타 아밀로이드 펩티드를 인식하는 인간화된 항체
TWI508975B (zh) 單株抗體
US12324855B2 (en) Method of safe administration of phosphorylated Tau peptide vaccine
KR101236611B1 (ko) 치료 백신
JP7701734B2 (ja) 抗aベータワクチン療法
US20050123553A1 (en) Amyloid beta-peptide and methods of use
WO2015165980A2 (en) Treatment and prevention of alzheimer's disease (ad)
JP3905126B2 (ja) T細胞媒介疾患の治療の効力を検出又は監視する方法
EA049756B1 (ru) Терапия с помощью вакцины против бета-амилоида
HK40058406A (en) Anti-abeta vaccine therapy
JP2026503655A (ja) 抗Aβワクチン療法
US20250049900A1 (en) Method of safe administration of tau phosphopeptide conjugate
HK40061379A (en) Method of safe administration of phosphorylated tau peptide vaccine
EA050855B1 (ru) ЛИПОСОМА ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ИНДУКЦИИ АНТИТЕЛ К ФОСФОРИЛИРОВАННОМУ ПЕПТИДУ Tau

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000